Last updated on February 2018

Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old


Brief description of study

This study focus on the comparison of CAG regimen to the low dose cytarabine therapy in elderly AML patients who are unfit or unwilling to receive intensive chemotherapy.

Detailed Study Description

Low dose cytarabine remains to be the choice of standard for elderly AML patients who are unfit or unwilling to receive intensive treatment. CAG regimen, which is a combination of aclacinomycinlow dose cytarabineG-CSF is used often in elderly AML patients in China. It is proved effective and safety in some pilot studieswhile there is no prospectiverandomized study yet.

Clinical Study Identifier: NCT02432911

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.